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Abstract 
Objective: Obesity and heart failure commonly coexist.. Some have reported an obesity 
paradox in heart failure suggesting that intentional weight loss may not necessarily be 
beneficial and guidance on this is lacking.  The aim of this study was to systematically review 
the outcomes following intentional weight loss in patients with heart failure and obesity. 
Method: A systematic review was undertaken using databases PUBMED, EMBASE, 
CENTRAL. Randomised control trials and observational studies were included.  
Results: 4 randomised controlled trials and 7 observational studies were identified. 
Randomised trials were small (n=<25), with the exception of one (n=100).Interventions 
included diet and exercise in 2, diet alone in 1 and use of orlistat in 1. All but 1 reported 
significant weight loss. 2 reported improvement in exercise capacity and quality of life. 1 
reported improvement in NYHA class. Observational studies, 5 of which reported outcomes 
following bariatric surgery, despite being small, heterogenous and high risk of bias, 
suggested a trend in improvement of left ventricular function, quality of life and exercise 
capacity following weight loss. 
Conclusion: Weight loss is achievable with lifestyle intervention in those with heart failure 
and obesity and may result in improvements in NYHA classification, quality of life and 
exercise capacity.  
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Abbreviations:  
HF: Heart Failure 
 HF-Pef: Heart failure with preserved ejection fraction 
 HF-Ref:Heart failure with reduced ejection fraction 
 BMI: Body mass index 
 ESC:European society of Cardiology 
 LV:Left ventricle 
 NYHA:New york heart association 
 RCT:Randomised control trials 
BNP:Brain natriuretic peptide 
QOL:Quality of life 
MHLF:Minnesota living with heart failure questionnaire 
KCCQ:kansas city cardiomyopathy questionnaire  
LVSD:Left ventricular systolic dysfunction 
 LVEF:Left ventricular ejection fraction 
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Introduction 
Obesity and heart failure (HF) commonly coexist. The prevalence of obesity in heart 
failure with reduced ejection fraction (HF-rEF) is between 30%1 and 40%2, and in heart 
failure with preserved ejection fraction preserved ejection fraction (HF-pEF) is between 41%3 
and 55%4. A body mass index (BMI) of greater than 30 is an independent risk factor for the 
development of heart failure.5 The risk increases by 5% in men and 7% in women for every 
1kg/m2 increase in BMI5, with an increased probability of developing heart failure with 
increasing duration of morbid obesity6.  
A specific “obesity” cardiomyopathy has been proposed7.  To what extent the development 
of HF in patients with obesity is due to specific pathophysiological processes of “obesity 
cardiomyopathy” or to concomitant conditions such as coronary artery disease, diabetes and 
hypertension is unclear.  Some have described an obesity paradox where patients with HF 
and obesity live longer than those with HF with normal or underweight8. Whether or not 
weight loss is beneficial in heart failure is therefore uncertain.  Current European Society of 
Cardiology (ESC) guidelines reflect this uncertainty by stating “for patients with moderate 
degrees of obesity (<31kg/m2) weight loss cannot be recommended as intentional reduction 
in BMI has not been shown to be beneficial or safe in heart failure with reduced ejection 
fraction. In more advanced obesity, weight loss can be considered for symptomatic benefit.”9  
Observational studies of intentional weight loss by bariatric surgery in patients and lifestyle 
interventions with obesity but without heart failure have reported reduction in left ventricle 
(LV) cavity size, LV mass, improved diastolic function, improved myocardial energetics and 
reduced myocardial triglyceride content.10-12 A large prospective nonrandomised study of 
bariatric surgery vs lifestyle intervention in individuals without heart failure showed significant 
improvements in diabetes, hypertension and lipid abnormalities in the surgical group at 10 
year follow up13. It can be hypothesised that these metabolic improvements may improve 
cardiac function and work alongside weight loss to metabolically and haemodynamically 
unload the failing heart in obesity.14 If improvements in cardiac morphology are seen in a 
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non-heart failure population with intentional weight loss should this translate into a heart 
failure population? 
We have performed a systematic review of the literature of intentional weight loss in heart 
failure with reduced and preserved ejection fraction.  How successful are different methods 
of weight loss in achieving weight loss?  What evidence is there for weight loss interventions 
improving measures of cardiac structure or function, cardiac biomarkers, symptoms, 
exercise capacity or quality of life?  
 
Methods 
Search Strategy 
Electronic databases (Embase, Medline and the Cochrane Central Register of Controlled 
Trials) were searched for key search terms occurring in the title, keyword or abstract. The 
search was carried out in November 2017 and included articles published between 1946 and 
2017.  Studies were limited to those published in English language, involving humans and 
patients aged over 18 years. Search terms were used to identify articles which included  
patients with a primary diagnosis of heart failure (either reduced or preserved ejection 
fraction) and obesity who underwent an intervention designed with the intention to reduce 
weight and reported on outcomes related to cardiac morphology, exercise capacity, New 
York heart association (NYHA) classification, cardiac biomarkers and quality of life.  
(“heart failure” OR “cardiac failure” OR “congestive heart failure” OR “congestive cardiac 
failure” OR “chronic heart failure” OR “NYHA” OR “HFREF” OR “HFPEF”) AND (“bariatric 
surgery” OR “gastric bypass” OR “Roux-en-Y Gastric Bypass” OR “sleeve gastrectomy” OR 
“gastric banding” OR “laparoscopic adjustable gastric band” OR “bilio-pancreatic diversion” 
OR “lifestyle” OR “weight management” OR “weight loss” OR “orlistat” OR “low energy” OR 
“low calorie” OR “diet” OR “dietician” OR “nutrition expert) AND (“cardiac geometry” OR 
“VO2max” OR “LVEF” OR “LV ejection fraction” OR “ejection fraction” OR “exercise 
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tolerance” OR “natriuretic peptide” OR “BNP” OR “nT-proBNP” OR “quality of life” OR 
“hospitalization” OR “medication use” OR “echocardiogram” OR “wall thickness”) 
Bibliographies, review articles and manuscripts identified through the search criteria were 
hand-searched for additional studies. Due to low numbers of randomised control trials (RCT) 
we have included both RCTs and observational studies.  Two reviewers (KM and JL) firstly 
reviewed all titles and abstracts independently with discrepancies being resolved at 
subsequent meeting and discussion. The systematic search process resulted in a total of 
3631 articles. After exclusions 11 articles were selected for review. (Figure 1) 
(Figure 1 here) 
Data Extraction and Synthesis 
KM abstracted and tabulated each study that met the inclusion criteria. An assessment of 
the risk of bias (Low/High) was made for each RCT using the Cochrane Collaboration tool15 
(Supplemetary Table 1). For observational studies, risk of bias was assessed using the 
National Institute of Health quality assessment tool for observational cohort and cross 
sectional studies16 (Supplementary Table 2). This systematic review was conducted and 
reported in accordance with the Cochrane handbook for systematic reviews.17  
Results 
Randomised Trials 
4 randomised control trials were identified18-21.(Figure 1)  3 of the trials included 21 patients 
or less 19-21.  One included 100 18.  Two trials were conducted in HF-rEF19-20 and one in HF-
pEF18.  The other did not report baseline ejection fraction21.   
Baseline Characteristics 
The baseline characteristics from the trials are shown in table 1a.  The mean age of 
participants in the trials was in the 50s (except for the largest trial of 100 patients where the 
mean age was 6718.  The mean BMI in all trials was high (39 to 42.4 kg/m2) despite inclusion 
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criteria of those who had a BMI in the range of overweight or obesity.  All RCTs reported the 
number of patients on evidence based heart failure medications including ace 
inhibitors/angiotensin receptor blockers and beta blockers but only one reported number of 
patients on mineralocorticoid receptor antagonists.  Two19-20 of the four trials required stable 
doses of medical therapy for HF, one specified a duration of 3 months19. None of the trials 
described optimisation of HF therapies. After randomisation one trial showed a significantly 
lower BMI in lifestyle ve control group20.      
Trial Design and Reporting (table 2a) 
One of the RCTs used a pharmacological intervention, orlistat19.  In two18,20 the intervention 
was diet and exercise, and the other diet alone21. One supplied the meals from the research 
centre18 and one made use of a meal replacement drink20. All three18,20-21 non-
pharmacological interventions involved advice from dieticians. Three19-21 of the RCT 
interventions lasted 12 weeks, one18 lasted 20 weeks.  1 trial used a Consolidated Standards 
of Reporting Trials (CONSORT) flow diagram18.  All but one study18 was thought to have a 
high risk of bias. (Supplementary table 1)  
Outcome Measures and Endpoints 
One trial18 provided a formal power calculation for primary outcomes. The other three19-21 did 
not. 
Weight loss and interventions 
 In three18-19,21 of the four RCTs, greater weight loss was achieved in the intervention group 
compared to the control group (table 3a). In one trial of only 20 patients there was no weight 
loss difference between groups20. 
Left ventricular systolic function. 
The two18-19 RCTs that reported on the effect of weight loss on left ventricular function did 
not report a significant effect (Table 3a).  The trial of 100 patients18 did report a reduction in 
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mean LV mass (-04[95% CI -7,0g) p=0.005), a reduction in left ventricular relative wall 
thickness (-0.03[95%CI, -0.05 to -0.01] p=0.05), and an increase in E/A ratio (0.1[95%CI, 
0.02-0.17]p=0.01) ,representing an improvement in diastolic function, with reduced calorie 
diet. 
BNP 
Neither of the two trials19,20 that reported brain natriuretic peptide (BNP) found a change with 
weight loss (table 3a). 
Exercise capacity 
All four RCTs18-21 reported on changes in exercise capacity associated with weight loss 
(Table 3a). This was based on 6 minute walk test in all and included maximal oxygen 
consumption at peak exercise (VO2max) measured by cardiopulmonary exercise test in 
two18,21. Of the two trials19-20 which did not demonstrate a significant improvement in exercise 
capacity, one was unable to demonstrate significant weight loss following a 12 week lifestyle 
intervention20. Of the two18,21which demonstrated an improvement in exercise capacity, one 
was the larger trial of 100 patients18 which reported a significant increase in exercise 
capacity as assessed by VO2max and 6 min walk distance. The effects were additive if both 
interventions were used together.  
NYHA Classification 
Two of the RCTs18,19 reported change in NYHA classification (table 3a). One18 included a 
HFpEF population only and reported a significant improvement in NYHA class as a result of 
diet and exercise induced weight change in this population. There was no demonstrable 
improvement in NYHA classification reported in a HFrEF population. 
QOL 
All four RCTs18-21 reported on health-related quality of life (HRQoL) (table 3a). Three18-19,21 
used Minnesota living with heart failure questionnaire (MLHF) with one additionally using 
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Kansas City cardiomyopathy questionnaire (KCCQ)18. 1 used KCCQ only20. One trial 
reported a significant improvement in MLHF score in n=5 patients randomised to a high 
protein diet21. The larger trial18 reported a significant improvement in HRQoL by diet, but not 
exercise based on KCCQ as an exploratory outcome.  
Observational Studies 
Seven6,22-27 observational studies were identified. The studies are small (n<50). Five 
studies6,22,24-25,27 measured results against control group however two control groups were 
non heart failure patients undergoing same intervention6,27 while three were heart failure 
patients undergoing no weight loss intervention22,24-25. Five studies were conducted on 
HFREF patients22-25,27. Two studies did not clarify EF6,26. 
Baseline Characteristics 
The baseline characteristics are shown in Table 1b, The mean BMI of participants ranged 
from 29.2-55kg/m 2 The mean age ranged from 38-68.2years. Three studies22,25,27 reported 
number of patients on heart failure therapies and patients were poorly optimised.  
Study Design and Reporting 
Five studies6,22-25 reported on outcome following bariatric surgery and included variety of 
laparoscopic and open procedures, including Roux-en-Y Gastric bypass, sleeve gastrectomy 
and gastric band. Both lifestyle interventions26-27 included diet, exercise and self 
management. All studies were found to have a high risk of bias. 
Outcome Measure and Endpoints 
Weight loss and Interventions 
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Substantial weight loss was achieved in all the bariatric surgery studies6,22-26. Significant 
weight loss from baseline to final weight was also seen in the studies involving lifestyle 
intervention26,27. 
Left ventricular systolic function 
One observational reported a significant improvement in ejection fraction following bariatric 
surgery compared to non surgical age, sex matched controls22. A trend towards 
improvement was also reported in two bariatric surgery studies23-24 and one lifestyle 
intervention study26. 
Exercise Capacity 
One study27 reported a significant improvement in exercise capacity measured by exercise 
tolerance test from baseline to end of study period. (12 months) 
QOL 
3 studies25-27 reported improvement in quality of life following weight loss intervention (two 
surgical, one lifestyle) Each used a different method to quantify quality of life and included 
KCCQ26, MOS-SF27 and a linear analogue self assessment questionnaire25. 
NYHA classification 
3 surgical studies6,22-23 and 1 lifestyle study26 reported improvement in NYHA following 
weight loss intervention. 
 
 
Discussion 
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Heart failure is a major cause of morbidity and mortality and poses a significant economic 
burden due to frequent readmission rates.28 Despite the very high prevalence of obesity in 
patients with heart failure, our systematic review found little definitive evidence regarding the 
impact of intentional weight loss on cardiac morphology and, perhaps more importantly, quality 
of life and exercise capacity in heart failure patients. However, trends towards improvements 
suggest significant results may be expected if flaws in trial designs were addressed.  
Importantly, there was no evidence of harm from intentional weight loss in this population. If a 
benefit to weight loss exists for patients with heart failure and co-existing obesity, then clear 
evidence and guidance on the most effective means of weight loss is required.   
 
Of the four trials18-21 included, only one included more than 21 patients18. The three smaller 
trials19-21 were feasibility studies and are too small to be adequately powered to demonstrate 
change. They did not include formal power calculations.This is a major limitation of this review. 
Although the mean BMI of participants across the trials ranged from 39-42.4kg/m 2 (class 3 
obesity) the BMI inclusion criteria were much lower and varied across all trials, two trials 
included patients with “overweight “ range BMI. (25kg/m2  in one20 trial and 27kg/m2 in 
another21) . The heart failure cohorts were variably optimised in terms of best heart failure 
therapies with changes in therapy throughout the interventions making it difficult to interpret 
outcomes as these therapies also reduce morbidy and mortality and improve quality of life. 
The interventions offered differed in terms of components 
(diet/exercise/pharmacotherapy/behavioural therapy) and frequency and duration of 
intervention. There was such a degree of heterogeneity of the intervention components and 
populations that meta-analysis would have had little meaning.  
 
Mortality analysis of heart failure populations suggest there may be a survival benefit for 
individuals with obesity compared to their lean counterparts. A meta-analysis of 2000029 
patients with HFREF and HFPEF followed up for 3 years showed that overweight patients had 
lower total and cardiovascular mortality risk compared to normal weight patients. Underweight 
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patients carried the worse prognosis. Those with more significant obesity had more 
hospitalisations when compared to normal weight patients but still carried lower mortality risk. 
A similar “protective effect” is seen across other chronic conditions30. Arguments against the 
existence of the obesity paradox include evidence based on many retrospective studies with 
failure to match cohorts adequately, the existence of a “time-lag bias” whereby those with 
obesity develop heart failure symptoms much sooner, a “selection bias” whereby only the 
healthiest patients with obesity live to develop heart failure. BMI has been the regularly used 
metric for obesity across these studies. Body composition may be more important, lean muscle 
mass is a major determinant of cardiorespiratory fitness in heart failure which has been shown 
to modify the obesity paradox31. A recent study reported loss of lean mass or sarcopenia was 
associated with lower muscle strength, exercise capacity and quality of life in patients with 
HFPEF32. These trials address the important question of whether intentional weight loss aimed 
at fat reduction is beneficial. Although the inclusion criteria for 2 of the trials included 
overweight range BMI patients20,21, the mean BMI in each trial included patients with class 3 
obesity making it difficult to draw firm conclusions if weight loss would have similar benefits 
across all classes of obesity. Only one trial18 used MRI to determine differences in body 
composition using MRI helping to separate intentional fat loss from the cachexia of heart 
failure. 
 
It has not been possible to determine if similar improvements in cardiac morphology to those 
without heart failure are seen following weight loss in patients with heart failure.  An 
improvement in left ventricular systolic dysfunction (LVSD) was not seen across the two 
trials18-19 which included this as an outcome. One trial19 included 21 patients and is therefore 
inconclusive. The other18 which assessed cardiac function using MRI included a HFpEF 
population only where no improvement in ejection fraction would be expected. The 
mechanism by which weight loss allows improvement of left ventricular morphology in a non-
heart failure population remains unclear and it is difficult to identify factors which would allow 
prediction of improvement or would identify when cardiomyopathy has progressed beyond 
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reversibility. Three observational studies22-24 suggested an improvement in left ventricular 
ejection fraction following bariatric surgery and one following lifestyle intervention26. The 
largest study24 compared 42 patients with documented LVSD to 2588 with no known pre-
operative heart failure but no definite exclusion of this. 38 of the 42 patients had a 
postoperative echo and were matched against non-surgical controls. The surgical group 
increased their ejection fraction significantly and linear regression analysis indicated those 
who improved their ejection fraction by more than 10% were less likely to have history of 
myocardial infarction. This is an important observation and suggests there is a cohort of 
patients who are more likely to respond than others, particularly after scar formation in 
ischaemic cardiomyopathy. However, this study is poorly designed and not conclusive. 4 
patients had cardiac resynchronisation therapy, 3 had valve intervention and 1 had coronary 
revascularisation between echocardiographs which could account for the reported benefit.  
None of the current studies6,22-27 or trials18-21, provided comparison of different aetiologies or 
types of heart failure on outcomes. Furthermore, the rise in left ventricular ejection fraction 
(LVEF) seen across the studies was minimal. The approximate range of error for 
measurement of LVEF is 5%23 and this may be amplified in this population with increasing 
body habitus decreasing the quality of imaging. Further studies using MRI as a more reliable 
imaging technique may help to understand the heterogeneity in LVEF response.  
Weight loss may improve many of the negative effects of obesity on the cardiovascular 
system not necessarily reflected by ejection fraction33  Diastolic dysfunction occurs more 
frequently than systolic dysfunction measured by ejection fraction although subclinical 
markers of LV contractile dysfunction using strain patterns have been reported.34 Increased 
adiposity promotes inflammation, hypertension, insulin resistance and dyslipidaemia and 
impairs cardiac, arterial and skeletal muscle and physical function35,36 all of which are 
common in heart failure with preserved ejection fraction and contribute to its 
pathophysiology18. These patients are difficult to treat, with very few evidence-based 
therapies available9. It has been shown that the severity of exercise intolerance, the main 
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determinant of quality of life in this patient group, correlates with increased adiposity18. It is 
important to be able to demonstrate if interventions which promote weight loss would be 
beneficial to their symptom load and quality of life. 
Following the improvement in medical care and mortality rates associated with heart failure 
there has been a shift in attention towards improvement in quality of life in those affected by 
heart failure. Quality of life assessment is emerging as an important tool to determine the 
clinical efficacy of medical treatments and evaluate the impact of specific treatments on the 
daily life of a patient18. Kitzman18 reported an improvement in KCCQ with diet but not exercise 
as an intervention. Diet did however lead to a greater weight loss than exercise overall. Quality 
of life is as important as survival to most patients living with chronic, progressive illness37..  
 
NYHA classification is used to assess symptom burden in patients with heart failure. Over 
80% of patients with heart failure have physical symptoms38. Worsening symptoms are the 
main antecedents of hospitalisations39.  Non-cardiac issues such as musculoskeletal and 
pulmonary limitations may also impair function. Observational studies suggest an 
improvement in NYHA following bariatric surgery and lifestyle-induced weight loss22,26. A 
significant improvement in NYHA was demonstrated in 100 patients with HFPEF following 
weight loss induced by diet or exercise18. Any improvement in NYHA from weight loss may 
not specifically be related to improvement in heart failure and may be multifactorial. For 
example, it may be related to a previously observed clinical improvement in the sleep 
apnoea/obesity hypoventilation syndrome with weight loss40.  While any process leading to 
improvements in functional capacity is welcomed, objective functional testing may be useful 
to provide insight into the mechanism of improvement in exercise capacity. In addition to 
improvement in NYHA, Kitzman18 reported that for obese HEFpEF patients, diet and 
exercise significantly increased exercise capacity as assessed by VO2max and 6 min walk 
distance, and that the effects were additive if both interventions were used together. An 
improvement in VO2max can be driven entirely by a reduction in weight however Kitzman18  
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also reported an improvement in other supporting factors which are independent of weight, 
including VO2 reserve, exercise time to exhaustion, workload and 6 minute walk test, 
suggesting a true improvement in exercise capacity. Leg power was also found to increase.” 
BNP is a useful biomarker to aid diagnosis of heart failure, assist with prognostication and 
quantify severity. None of the trials reported an improvement in BNP with weight loss. The 
reported values of BNP were low. The observational studies did not use natriuretic peptide 
however the study dates may mean that the commercial use of BNP was not widely 
available These modest BNP results could result from well-compensated, non-hospitalised 
participants. However, an inverse relationship between obesity and BNP levels has been 
shown to exist.41 Increasing levels of BNP seem to retain prognostic capacities although 
increased risk may be seen at lower BNP values in an obese compared to lean heart failure 
population.42 This makes any change with weight loss difficult to interpret.  
Bariatric surgery has been acknowledged as the obesity treatment with the most durable 
success43 and in a heart failure free population has demonstrated that the resultant weight loss 
leads to reduction in LV mass and diastolic dysfunction44. Safety concerns have limited the 
use of bariatric surgery in patients with heart failure and there have been no trials of such 
performed. One observational study22 reported bariatric surgery to be safe, effective and 
durable in this patient population. 12 patients with HFrEF underwent bariatric surgery leading 
to a median length of hospital stay of 3+/-1.5 days. Post-operative complications included 
pulmonary oedema in 1 patient and transient acute kidney injury in another. These results 
were achieved with management by an experienced multidisciplinary team of cardiologists, 
bariatric surgeons and intensivists in specialist centres, with optimisation of haemodynamics 
and pharmacotherapy prior to surgery which may not be routinely available. This inadequately 
controlled, retrospective, small study makes it impossible to draw firm conclusions about the 
safety of this procedure in the general heart-failure population. A larger observational study45 
(n=524) reported a significant reduction in postoperative heart failure hospitalisation for 
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patients with heart failure who had undergone bariatric surgery in a self-controlled case-series 
but did not report on overall weight loss or changes in cardiac morphology on imaging. 
 
One of the biggest challenges in assessing the impact of weight loss in heart failure patients 
is establishing which weight loss intervention is best and could be broadly implemented. 
Although successful weight loss can be challenging, all but one trial20 demonstrated significant 
weight loss via non-surgical interventions. A modest 5-10% weight loss via lifestyle change 
has been shown to improve the cardiovascular risk profile by decreasing hypertension, 
dyslipidaemias and type 2 diabetes46. Of the successful interventions used, one achieved 
weight loss with orlistat and one with diet alone. Only one successful intervention included a 
combination of diet, focussing on achieving calorie deficit, exercise and individualised 
behavioural counselling; Lifestyle interventions designed to modify behaviours and physical 
activities are the first-line recommended option for weight management47. Due to the level of 
input required from the research centre to implement the interventions described (providing 
meals), this would not be easily repeatable for use in a routine care setting. However the 
principles used, of diet and exercise in addition to group interaction, are important. Extensive 
evidence has shown that in order to achieve and maintain weight loss behavioural counselling 
is essential48. Recommendations on diet alone results in minimal weight loss47.  Successful 
weight loss has been achieved through lifestyle modification programmes with frequent 
interactive encounters, goal setting, self-monitoring, stimulus control and problem solving49. 
These open-group behavioural weight loss programmes are both clinically and cost-effective 
and commercial programmes are now recommended by NICE50 and are available across the 
UK and internationally. In addition to any benefit of weight loss the “self-care” behaviours 
required when adhering to these programmes may impact positively on patients quality of life. 
Patients perceive that self-care behaviours and better social support improve quality of life51.  
In order for weight loss to be effective it must be able to be maintained. All the trials18-21  
included in this review involved interventions lasting less than 20 weeks. Pharmacotherapy 
with orlistat has been shown to improve weight loss only after one year of therapy44. Patients 
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are often disappointed with a moderate degree of weight loss and weight regain is common 
after termination of drug treatment44. The improvements in cardiac morphology seen after 
bariatric surgery (non-heart failure population) in the UTAH study were reported at 2 years10. 
Longer interventions and longer follow-up of outcomes maybe required. 
 
The results of this review are promising as they may indicate that improvements in heart failure 
symptoms, quality of life and exercise capacity may be possible for patients with obesity and 
heart failure as a result of a weight-loss intervention. However, the results are preliminary 
rather than definitive due to significant design and methodological limitations. The use of 
prolonged, multicomponent, evidence-based intentional weight loss regimes may provide 
firmer evidence to allow for future clinical guidance.  
 
Conclusion 
Obesity is highly prevalent amongst patients with heart failure. Advice regarding weight 
management is difficult due to the lack of evidence-based guidelines. Other than restricting 
sodium intake to <2g per day there are no specific dietary heart failure guidelines52. 
Intentional weight loss in a patient with co-existent obesity and heart failure may improve 
exercise capacity, NYHA classification and quality of life. These advantages could be 
achieved with small, sustained changes to body weight. To date, trials have been small with 
considerable heterogeneity, using weight loss interventions that do not match best-practice, 
but trends suggest weight loss is achievable. Bariatric surgery may be safe in heart failure 
patients through intensive optimisation of pre-operative state and a multidisciplinary 
approach. Prospective randomised clinical trials using evidence-based weight management 
interventions, sufficiently powered to assess clinical outcomes, are required to aid 
management of this complex, comorbid population.  
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Table and Figure Legends 
Figure 1: Flow chart of the Literature search process. 
 
Table 1A: Trial design and outcome measures: randomised controlled trials 
ACS: acute coronary syndrome, BNP: brain natriuretic peptide, BMI: body mass index, 
CPET: cardiopulmonary exercise test, EF: ejection fraction, ETT: exercise treadmill test. HF: 
heart failure, KCCQ: Kansas City cardiomyopathy questionaire. LTFU: lost to follow up, MI: 
myocardial infarction, MLHF: Minnesota living with heart failure questionaire, NCEP III: 
National cholesterol education program III, ND: not defined, NHANES: National health and 
nutrition examination survey, NYHA: New York heart association classification, PAP: 
pulmonary artery pressure. QOL: quality of life, 6MWT: 6-minute walk test,  
*Duration was predefined 
 
Table 2A: Baseline characteristics: randomised control trials 
Acei/ARB: angiotensin-converting-enzyme inhibitor/angiotensin receptor blocker, BB: beta 
blocker, BMI: body mass index, CRT: cardiac resynchronisation therapy, EF: ejection 
fraction,  HF: heart failure, ICD: implantable cardiac defibrillator, IHD: ischaemic heart 
disease, MRA: mineralocorticoid receptor antagonist. ND: not defined. 
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Table 3A: Results: randomised controlled trials 
BNP: brain natriuretic peptide, EF: ejection fraction, NS: non-significant, KCCQ: Kansas City 
cardiomyopathy questionnaire, MLHF: Minnesota living with heart failure questionnaire, 
NYHA: New York heart association classification, SD: standard deviation 
 
Table 1B Trial design and outcome measures: observational studies 
BMI: body mass index, CABG: coronary artery bypass graft, EF: ejection fraction, ETT: 
exercise tolerance test, HF: heart failure, KCCQ: Kansas city cardiomyopathy questionnaire, 
LMS: left main stem, LTFU: lost to follow up, MLDP: multicentre lifestyle demonstration 
project, MOS-SF: medical outcomes study-short form survey, ND: not defined, NYHA: New 
York heart association, QOL: quality of life,  
 
Table 2B: Baseline Characteristic of intervention group: Observational Studies 
Acei/ARB: angiotensin-converting-enzyme inhibitor/angiotensin receptor blocker, BB: beta 
blocker, BMI:body mass index,CRT: cardiac resynchronisation therapy, EF: ejection fraction,  
HF:heart failure, ICD: implantable cardiac defibrillator, IHD: ischaemic heart disease, MRA: 
mineralocorticoid receptor antagonist. ND: not defined 
 
Table 3b results: observational studies 
EF: ejection fraction, ETT: exercise tolerance test, FS: fractional shortening, KCCQ: kansas 
city cardiomyopathy questionnaire, LSAQ: linear analogue self assessment questionnaire, 
MOS-SF: medical outcomes study-short form survey ND: non described, NS: Non 
significant, NYHA: new york heart association,  
*% weight mean weight loss,  
‡median and range values 
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•control group used patients without heart failure undergoing same intervention 
×Weights not defined therefore weight in kg calculated from body mass index figures given 
using a standard height of 1.7m 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1A:  Trial design and outcome measures: randomised controlled trials 
Study/ 
Year/ 
Country 
Key heart failure 
inclusion criteria 
Key obesity 
inclusion 
criteria 
Key exclusion  
criteria 
Recruitment 
dates 
Multi-
center 
CONSORT 
diagram  
Duration* 
weeks 
LTFU 
% 
 
Intervention Outcome measure(s) of interest 
HEFPEF     
Kitzman  
2016 
USA 
 
-EF >50% 
-Signs and 
symptoms HF 
(NHANES >3 or 
Rich et al 
criteria45 
-Biomarkers not 
included 
 
-BMI >30 -Wall motion 
abnormality  
-significant 
ischemic or 
valvular disease 
-pulmonary 
disease 
-anaemia 
-undergoing 
regular 
diet/exercise 
2009-14 No Yes 20 
 
8 Lifestyle Modification  
Randomised to 4 groups: 
1: Exercise alone: 1 hour 
supervised session 3x per 
week. Personalised 
intensity 
2. Diet alone: hypocaloric 
diet.  Meals prepared by 
research centre. Aim 
400kcal deficit. 30% fat. 
1.2g/kg protein 
3. Diet and Exercise. Aim 
350kcal deficit 
4. Control-no diet or 
exercise  
for duration of study. 
Received 2 weekly phone 
calls to match interaction 
of other group 
Primary Outcome 
1) Exercise capacity by V02max 
2) QOL by MLHF 
Exploratory outcomes 
1) Exercise capacity by ETT and 6MWT 
2) QOL by KCCQ 
3) NYHA class 
4) Left ventricular function by EF 
measured on cardiac MRI 
5) BNP 
HEREF     
Beck de Silva, 
2005,  
USA 
 
-EF < 40% 
(measured by 
radionuclide 
angiography) 
-NYHA II-IV 
-stable doses of 
conventional HF 
medical therapy 
for 3 months 
-Biomarkers not 
included 
-BMI>30 
-weight 
stability for 
3 months 
-Eating disorder 
-Previous weight 
reduction surgery 
ND No  No 12 
 
10 Pharmacotherapy   
Randomised to 2 groups: 
orlistat three times daily 
plus multivitamin plus 
standard care vs 
standard care alone 
(dietician referral, 
prescription of low 
calorie diet, restricted 2g 
Na per day) 
Primary and secondary endpoints ND 
1) Exercise capacity by 6MWT  
2) Left Ventricular function by 
radionuclide ventriculography  
3) NYHA class 
4) BNP  
5) QOL by MHLF3  
 
Pritchett 
2012 
USA 
-EF <50% 
Framingham 
criteria 
-NYHA II-III 
-Stable doses of 
conventional HF 
medical therapy 
(duration ND) 
-Biomarkers not 
included 
-BMI>25 
-With 
Metabolic 
syndrome 
(NCEP III 
definition) 
-NYHA IV 
-Weight 
loss>10lbs 
previous 3 
months 
 
2005-8 No No 12 5 Lifestyle Modification  
Randomised to 2 groups: 
1) Standard HF care plus 
diet and exercise 
program 
 Initial 1 hour education 
session on self care, salt 
and fluid restriction. 
-Diet-Portion control diet 
including 2 meal 
Primary and secondary endpoints ND 
1) Exercise capacity by 6MWT 
2) BNP 
3) QOL by KCCQ 
replacement products 
(Slimfast), one portion 
controlled snack and self-
selected meal, given 
kilocalorie goal based on 
weight. <30% fats, <10% 
saturated fats 
-Exercise-unsupervised 
walking. Advised to 
achieve moderate 
exertion. provided with 
pedometer  
-Behavioural adaptation- 
weekly scheduled group 
meetings with dietician 
with education on diet, 
exercise and personalised 
tailoring of the program 
to achieve goal 
2)  Standard medical 
heart failure care only 
EF Uncertain     
Evangelista 
2009 
USA 
-NYHA II-III  
-EF not included 
-Biomarkers not 
included 
 
-BMI>27 
-type 2 
diabetes 
mellitus 
(non insulin 
treated) 
 
-Weight loss 
>10% in last 6 
months 
-already involved 
in weight loss 
programme 
 
ND  No No 12 0 Lifestyle Modification  
Randomised to 3 groups-  
1.HP: High protein, 
hypoenergetic diet (40% 
carbohydrates, 30% 
protein, 30% fat) 
2.SP: Standard protein, 
hypoenergetic diet (55% 
carbohydrate, 15% 
protein, 30% fat) 
3. conventional diet with 
no energy restrictions- 
high carbohydrates, high 
fibre, low fat.  
Primary and secondary endpoints ND 
1) Exercise capacity by 6MWT and CPET: 
VO2max 
2) QOL by MHLF 
 
  
ACS: acute coronary syndrome, BNP: brain natriuretic peptide, BMI: body mass index, CPET: cardiopulmonary exercise test, EF: ejection fraction, ETT: exercise treadmill test. HF: heart failure, KCCQ: Kansas City 
cardiomyopathy questionaire. LTFU: lost to follow up, MI: myocardial infarction, MLHF: Minnesota living with heart failure questionaire, NCEP III: National cholesterol education program III, ND: not defined, 
NHANES: National health and nutrition examination survey, NYHA: New York heart association classification, PAP: pulmonary artery pressure. QOL: quality of life, 6MWT: 6-minute walk test,  
*Duration was predefined 
 
 
  
Table 1b: Trial design and outcome measures: observational studies 
Study/ 
Year/ 
Country 
Key HF 
Inclusion 
criteria 
Key Obesity 
inclusion 
criteria 
Key Exclusion  
criteria 
Control Group Recruitment 
dates 
Multi-
center 
LTFU 
 
Follow 
up 
Intervention Outcome measure(s) 
HFREF      
McCloskey  
2006 
USA 
EF <35% 
Biomarkers not 
included 
Symptoms ND 
BMI >40 
Undergone 
bariatric 
surgery 
ND No Control 1998-06 No 15 3-89 Surgical 
-10 Laparoscopic Roux en Y Gastric 
bypass 
-1 open Roux en Y Gastric bypass 
-2 sleeve gastrectomy 
-1 laparoscopic adjustable gastric 
band 
1) Left ventricular function by EF- 
echo or catheterization 
2) NYHA 
Miranda 
2013 
USA 
1 of 
EF <50% 
Documentation 
of clinical 
diagnosis 
Echo evidence 
of diastolic 
dysfunction 
Biomarkers not 
included 
BMI>35 
referred for 
evaluation 
of bariatric 
surgery 
ND Non surgical 
patients with 
obesity and 
heart failure. 
Managed at 
nutrition clinic 
by cardiology, 
endocrinology 
and nutritionist 
1990-05 No  23 ND Surgical 
Roux-en-Y Gastric Bypass 
1)Left ventricular function by EF 
2) HF Symptoms by likert scale  
3) QOL by linear analogue self 
assessment questionnaire 
  
Ramani 
2008 
USA 
“advanced 
systolic heart 
failure” 
EF not included 
Biomarkers not 
included 
Symptoms ND 
 
“Morbid 
Obesity” 
ND Non surgical 
age, sex, BMI 
matched.  
2001-06 No 0  12 Surgical 
8 laparoscopic Roux-en-Y Gastric 
Bypass 
2 laparoscopic sleeve gastroplasty 
1 laparoscopic gastric band 
1 opne Roux-En-y Gastric Bypass 
1) Left ventricular function by EF 
(echo) 
2) NYHA 
Vest 
2015 
USA 
EF <50% 
Biomarker not 
included 
Symptoms ND 
Undergone 
bariatric 
surgery 
ND Subgroup of 
patients with 
pre and post 
procedure echo 
matched to non 
surgical heart 
failur patients 
with obesity 
 
2004-13 No 0 23 Surgical  
Roux-en-Y gastric bypass, 
Adjustable gastric banding 
Sleeve gastrectomy 
1) Left ventricular function by EF 
(echo) 
 
 
 
Pischke 
2007 
USA 
 
 
 
 
 
EF <40%  
NYHA I-II 
Biomarkers not 
included 
 LMS >50% 
CABG 6 weeks 
Angioplasty 6 
months 
 
Ejection fraction 
>40% 
1993-97 Yes 24 12 Lifestyle (52 weeks) 
Initial 12 week 3 group sessions on 
diet/exercise/ stress management / 
Remaining 40 weeks 1 group session 
per week 
Goal-10% calories from fat based on 
3 day food diary, 3h exercise per 
week, 1 hour yoga/meditation, 
attendednce at sessions 
1)QOL by MOS SF 34 
2) Exercise capacity by ETT 
 
EF uncertain      
Alpert 
1997 
USA 
HF((Framingha
m study) 
EF not included 
Biomarkers not 
included 
 
Body weight 
>twice ideal 
body weight 
Hypertension 
Evidence of 
coronary 
artery diease 
Uninterpretab
le echo 
Patients 
without heart 
failure 
undergoing 
surgery 
ND No 42 4.5+/-
1.2 
Surgical 
Vertical band gastroplasty 
1) Left ventricular function by FS 
2)NYHA  
Marriotti 
2008 
Italy 
EF not included 
Biomakers not 
included 
Symptoms ND 
-BMI >27.8 
 
ND No control 
 
ND No 15 6  Lifestyle (6 months) 
Personalised Hypocaloric diet 
Encouraged exercise 
Diaries to identify and adjust eating 
habits 
1)Left ventricular function by 
-EF measured by echo 
2) NYHA 
3) QOL by KCCQ 
BMI: body mass index, CABG: coronary artery bypass graft, EF: ejection fraction, ETT: exercise tolerance test, HF: heart failure, KCCQ: Kansas city cardiomyopathy questionnaire, LMS: left main stem, LTFU: lost to 
follow up, MLDP: multicentre lifestyle demonstration project, MOS-SF: medical outcomes study-short form survey, ND: not defined, NYHA: New York heart association, QOL: quality of life,  
 
 
 
 
 
 
 
Table 2A: Baseline characteristics: randomised control trials 
Study/ 
(Year)/ 
Country 
Setting 
 
Number of 
participants 
 (n) 
Age, years, 
(mean) 
Female 
(%) 
Weight,kg 
(mean) 
BMI, kg/m2 
(Mean) 
Mean EF 
(%) 
HF Therapy  
(%) 
Comorbidites (%) 
    
Beck de Silva 
2005 
USA 
Outpatients 
 
 
21 50 19 126 42 27 ACEi/ARB (100) 
BB (90) 
MRA-ND 
CRT/ICD ND 
Diabetes Mellitus (29) 
Hypertension ND 
IHD ND 
          
Evangelista  
2009 
USA 
Outpatients 
 
  
 
14 59 22 106 38 26 
 
ACEi/ARB (93) 
BB (93) 
MRA-ND 
CRT/ICD ND 
 
Diabetes Mellitus (100) 
Hypertension (71) 
IHD (50) 
 
Kitzman  
2016 
USA 
Outpatients 
 
 
 
100 67 81 106 39 61 ACEi/ARB (72) 
BB (40) 
MRA-ND 
CRT/ICD ND 
 
Diabetes Mellitus (35) 
Hypertension (95) 
IHD-ND 
Pritchett 
2012 
USA 
 
 
 
 
 
Outpatients  
 
20 52 30 ND 39 26 ACEi/ARB (90) 
BB (100) 
MRA (50) 
CRT/ICD (5/35) 
Diabetes Mellitus (70) 
Hypertension (90) 
IHD (35) 
 
 
 
 
 
 
 
Acei/ARB: angiotensin-converting-enzyme inhibitor/angiotensin receptor blocker, BB: beta blocker, BMI: body mass index, CRT: cardiac resynchronisation therapy, EF: ejection fraction,  HF: heart failure, ICD: 
implantable cardiac defibrillator, IHD: ischaemic heart disease, MRA: mineralocorticoid receptor antagonist. ND: not defined. 
 
 
 
 
  
Table 2B: Baseline Characteristic of intervention group: Observational Studies. 
Study/ 
Year/ 
Country 
Setting 
 
Number of 
participants 
Intervention 
 (n) 
Number of 
participants 
in control 
Age, years, 
(mean) 
Female 
(%) 
Weight,kg 
(mean) 
BMI, kg/m2 
(Mean) 
Mean EF 
(%) 
HF Therapy  
(%) 
Comorbidites 
described(%) 
     
Lifestyle Intervention     
Marriotti 
2008 
Italy 
 
Outpatients 
 
 
40 No control 68.2 35 92.9 31.8 33.5 ND Diabetes Mellitus (29.4) 
Hypertension (79.4) 
IHD (45) 
Pischke 
2007 
USA 
 
Outpatients 50 186 57 18 89 29.2 ND AceI/ARB (58)  
BB (66) 
MRA (ND) 
Diabetes Mellitus (20) 
Hypertension (56) 
IHD (100) 
Surgical  Intervention     
Alpert 
1997 
USA 
Outpatient 24 50 38 79 128 ND ND ND ND 
           
McCloskey 
2006 
USA 
Database 14 No control 46 29 ND 50.8 23 ND Diabetes Mellitus (58) 
Hypertension (64) 
IHD (29) 
           
Miranda‡ 
2013 
USA 
 
Database 13 6 62 62 146 55 57 AceI/ARB(54) 
BB (46) 
MRA (ND) 
Diabetes Mellitus (77) 
Hypertension (92) 
IHD (ND) 
Ramani 
2008 
USA 
 
Database 12 10 41 75 ND 53 22 AceI/ARB (92) 
BB (67) 
MRA (36) 
Diabetes Mellitus (50) 
Hypertension (75) 
IHD (17) 
           
Vest 
2015 
USA 
Database 
 
38 
 
38 50 47 ND 47.2 38 ND Diabetes Mellitus (61) 
Hypertension (71) 
IHD (50) 
           
 
Acei/ARB: angiotensin-converting-enzyme inhibitor/angiotensin receptor blocker, BB: beta blocker, BMI:body mass index,CRT: cardiac resynchronisation therapy, EF: ejection fraction,  HF:heart failure, ICD: 
implantable cardiac defibrillator, IHD: ischaemic heart disease, MRA: mineralocorticoid receptor antagonist. ND: not defined 
 
 
Table 3A: Results: randomised controlled trials 
Study              Measure Mean change Intervention group/ 
Main change effect in Intervention 
factorial groups‡ 
Mean change control group/ 
 
p value 
Weight loss    
Beck de Silva kg -4.65+/-9.8 
 
 +4.39+/-7.4                                                  <0.001  
Evangelista 
(High Protein) 
Kg 
 
-9.9+/-2 
 
 -1.5+/-0.6                                                     <0.05 
Evangelista 
(Standard Protein) 
kg -5.6+/-0.8 
 
 -1.5+/-0.6                                                     <0.05 
Pritchett kg -1.2+/-4.1  -0.56+/-3.71                                                0.71 
Kitzman 
(Exercise) 
kg -3(-5,-1)‡  NA                                                                 <0.001 
Kitzman 
(Diet) 
kg -7(-9,-5)‡  NA                                                                 <0.001 
Exercise Capacity    
Beck de Silva 6 minute walk test (m) +45.8 (No SD) 
 
 +14.9(No SD)                                             0.17 
Evalgelista 
(High Protein) 
6 minute walk test (m) 
V02max(ml/kg/min) 
+287.3+/-69 
+3.1+/-1 
 -138.4+/-77.1                                            <0.05 
-0.3+/-1/1 
Evangelista 
(Standard Protein)  
6minute walk test (m)  
VO2max(ml/kg/min) 
-12.3+/-69 
-0.3+/-1.0 
 -138.4+/-77.1                                             <0.05 
                               
-0.3+/-1/1 Pritchett 6 minute walk test(m) +169+/-235  +84 -41                                                    0.59 
Kitzman 
(Exercise) 
6 minute walk test (m) 
V02 max (ml/kg/min) 
106(60,152)‡ 
+1.2(0.7,1.7)‡ 
 Not reported                                     <0.0001 
                                                                     <0.0001 
Kitzman 
(Diet) 
6 minute walk test(m) 
V02 max (ml/kg/min) 
85(39,132)‡ 
+1.3(0.8,1.8)‡ 
 Not reported                                              0.0005 
                                                                     <0.0001 
Quality of Life    
Beck de Silva MLHF Not reported  Not reported                                             Not reported 
Evangelista 
(High Protein) 
MLHF -20.1+/-9.5  -5.1+/-3.9                                                    <0.05 
Evangelista 
(Standard Protein) 
MLHF -12.2+/-4.3  -5.1+/-3.9                                                    NS 
Pritchett KCCQ +6.1+/-18.6  +1/7+/-10                                                    0.55 
Kitzman 
(Exercise) 
MHLF 
KCCQ 
-1(-8,5)‡ 
2(-3,7)‡ 
 Not reported                                              0.7 
                                                                      0.43 
Kitzman 
(Diet) 
MHLF 
KCCQ 
-0.6(-12,1)‡ 
7(3,12)‡ 
 Not reported                                              0.078 
                                                                      0.004 
NYHA Classification    
Beck de Silva NYHA +0.6+/-0.5 
 
 -0.2+/-0.8                                                      0.25 
Kitzman  
(Exercise) 
NYHA -0.4(-0.6,0.2)‡  Not reported                                                0.001 
Kitzman 
(Diet) 
NYHA -0.4(-0.5,-0.2)‡  Not reported                                               0.001 
BNP    
Beck de Silva BNP (pg/ml) -32.3+/-313.5  -67.5+/-95.1                                                  0.742 
Pritchett BNP(pg/ml) -5(-28,20.5)  +4(-39,18)                                                     1 
Left ventricular Ejection Fraction     
Beck de Silva EF(%)   Not reported                                             Not reported                                                  NS  
Kitzman  
(Exercise) 
EF(%)  0(-2,2)‡                                            Not reported                                                  NS  
Kitzman 
(Diet) 
EF(%)  -1(-3,1)‡                                           Not reported                                                   NS                                                            
 
BNP: brain natriuretic peptide, EF: ejection fraction, NS: non-significant, KCCQ: Kansas City cardiomyopathy questionnaire, MLHF: Minnesota living with heart failure questionnaire, NYHA: New York heart 
association classification, SD: standard deviation 
 
Table 3b results: observational studies 
  Intervention Group Control Group• P value 
Study Measure Baseline 
measure 
group 
Mean+/- sd 
Final measure 
group 
Mean change 
measure 
group* 
Baseline measure 
group 
 
Mean+/-sd 
Final measure  
group 
Mean change 
measure 
group 
Intervention 
change vs control 
change 
Intervention baseline vs 
final 
Weight      
Miranda‡ kg 146(98-210) 99(63-164) ND 132(112-147) 140(124-128) ND <0.001 ND 
Ramani kg× 153.1+/-20 110+/-23 ND 136+/-12 136+/-12 ND ND <0.01 
Vest kg× 47.2+/-10 ND 22.6* 38.2+/-7 NS 0.08* <0.001 ND 
Pischke• kg 
 
90.5+/-17.1 84.1+/-15.8 ND NA NA NA NS <0.001 
Alpert• kg  128+/-16 ND 33+/-4* NA NA NA NS ND 
Marriotti kg 92.9+/-10.6 88.5+/-10.4 ND No control No control  No control  No control <0.004 
McCloskey kg× 147+/-6 107+/-5 41.9 No control No control  No control  No control ND 
Exercise Capacity     
Pischke ETT 8.9+/-3.4 10.6+/-2.7 ND NA NA NA NS <0.01 
Quality of Life     
Miranda‡ LSAQ 3(0-6) 7(7-10) 5(-10-10) 4.5(3-8) 6(3-8) 0(0-3) 0.06 0.001 
Pischke• MOS SF36-PH 
MOS SF36-MH 
44.8+/-10.3 
48.2+/-10.9 
49.4+/-8.9 
52.9+/-11.4 
ND NA NA NA              NS <0.01 
<0.01 
Mariotti KCCQ 59.7+/-21.7 71.2+/-19.3 ND No control No control  No control  No control 0.02 
Heart Failure symptoms     
Ramani NYHA 2.9+/-0.7 2.3+/-0.5 ND 2.4+/-0.7 3.3+/-0.9 ND <0.05 0.02 
Alpert• NYHA 2.5+/-0.5 1.4+/-0.5 ND N/A N/A          N/A N/A ND 
Mariotti NYHA 2.3+/-0.9 1.9+/-0.7 ND No control No control  No control  No control <0.05 
McCloskey NYHA 2.7+/-0.4 2.2+/-0.4 ND No control No control  No control  No control ND 
Left ventricular Function      
Miranda‡ EF(%) 57(35-75) 59(41-75) ND 57.5(35-65) 62.5(53-65) ND NS NS 
Ramani EF(%) 21.7+/-6.5 35+/-14.8 ND 23.5+/-6.7 28.5+/-14 ND <0.05 <0.01 
Vest EF(%) 37.8+/-9 ND +5.1+/-8.3 37.4+/-9 ND +3.4+/-10.5 ND P=0.0005 
Alpert• FS(%) 23+/-5 ND +5+/-5 NA NA NA NS NS 
Mariotti EF(%) 33.5+/-11.5 37.4+/-12.1 ND No control No control  No control  No control 0.02 
McCloskey EF(%) 23+/-6 33+/-14 12.2+/-14.6 No control No control  No control  No control 0.02 
EF: ejection fraction, ETT: exercise tolerance test, FS: fractional shortening, KCCQ: kansas city cardiomyopathy questionnaire, LSAQ: linear analogue self assessment questionnaire, MOS-SF: medical outcomes 
study-short form survey ND: non described, NS: Non significant, NYHA: new york heart association,  
*% weight mean weight loss,  
‡median and range values 
•control group used patients without heart failure undergoing same intervention 
×Weights not defined therefore weight in kg calculated from body mass index figures given using a standard height of 1.7m 
